Sobi's 2011 Long-Term incentive Programme meets all objectives

Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2011 Long-Term Incentive programme met its objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2011 programme is 514 808.

---

More information about Sobi's 2011 long-term incentive programme can be found in Sobi's Annual Report 2013.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on Nasdaq OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations  
Oskar Bosson, Head of Communications   
T: +46 70 410 71 80
oskar.bosson@sobi.com                                                                                  

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com